4 aminosalicylic acid

4-Aminosalicylic acid hemicalcium, an orally active antibiotic, shows potential in tuberculosis research [1].

4-Aminosalicylic acid-d6 is the deuterium-labeled version of 4-Aminosalicylic acid. This compound acts as an inhibitor of dihydrofolate reductase (DHFR) and serves as an anti-tuberculosis medication. Additionally, 4-Aminosalicylic acid exhibits anti-inflammatory properties, making it useful for research in inflammatory bowel disease (IBD). It is also orally active.

4-Aminosalicylic acid (para-aminosalicylic acid) is an analog of para-aminobenzoic acid (PABA) with antitubercular activity.

Sodium 4-aminosalicylate dihydrate (4-Amino-salicylic acid sodium salt) is the sodium salt form of aminosalicylic acid, an analog of para-aminobenzoic acid (PABA) with antitubercular activity. Sodium 4-aminosalicylate dihydrate exerts its bacteriostatic activity against Mycobacterium tuberculosis by competing with PABA for enzymes involved in folate synthesis, thereby suppressing growth and reproduction of M. tuberculosis, eventually leading to cell death.

4-Aminosalicylic acid (Standard) is the standard substance of 4-Aminosalicylic acid, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. 4-Aminosalicylic acid (para-aminosalicylic acid) is an analog of para-aminobenzoic acid (PABA) with antitubercular activity.

Olsalazine-13C6 is intended for use as an internal standard for the quantification of olsalazine by GC- or LC-MS. Olsalazine (T20615) is an orally bioavailable prodrug form of the anti-inflammatory agent 5-aminosalicylic acid that is cleaved by bacterial azo reductases in the gut to generate active 5-ASA.1